201. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice.
- Author
-
Moroncini, Gianluca, Paolini, Chiara, Orlando, Fiorenza, Capelli, Chiara, Grieco, Antonella, Tonnini, Cecilia, Agarbati, Silvia, Mondini, Eleonora, Saccomanno, Stefania, Goteri, Gaia, Svegliati Baroni, Silvia, Provinciali, Mauro, Introna, Martino, Del Papa, Nicoletta, and Gabrielli, Armando
- Subjects
- *
STROMAL cells , *UMBILICAL cord , *PULMONARY fibrosis , *IMMUNOCOMPETENT cells , *LABORATORY mice , *PHYSIOLOGY - Abstract
Lung fibrosis is a severe condition resulting from several interstial lung diseases (ILD) with different etiologies. Current therapy of ILD, especially those associated with connective tissue diseases, is rather limited and new anti-fibrotic strategies are needed. In this study, we investigated the anti-fibrotic activity in vivo of human mesenchymal stromal cells obtained from whole umbilical cord (hUC-MSC). Adult immunocompetent C57BL/6 mice (n. = 8 for each experimental condition) were injected intravenously with hUC-MSC (n. = 2.5 × 105) twice, 24 hours and 7 days after endotracheal injection of bleomycin. Upon sacrifice at days 8, 14, 21, collagen content, inflammatory cytokine profile, and hUC-MSC presence in explanted lung tissue were analyzed. Systemic administration of a double dose of hUC-MSC significantly reduced bleomycin-induced lung injury (inflammation and fibrosis) in mice through a selective inhibition of the IL6-IL10-TGFβ axis involving lung M2 macrophages. Only few hUC-MSC were detected from explanted lungs, suggesting a “hit and run” mechanism of action of this cellular therapy. Our data indicate that hUC-MSC possess strong in vivo anti-fibrotic activity in a mouse model resembling an immunocompetent human subject affected by inflammatory ILD, providing proof of concept for ad-hoc clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF